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Introduction
Clinical guidelines for the prevention of cardiovascular disease (CVD) (coronary heart disease [CHD], thrombo-embolic cerebrovascular disease and peripheral vascular disease) have evolved rapidly over the last 20 years. The ¢rst national guidelines were produced by specialist societies, gave authoritative advice in relation to the management of key individual risk factors and were largely consensual. 1,2 These guidelines were brought together by the conclusions of a joint working party of the British Cardiac Society, the British Hyperlipidaemia Association and the British Hypertension Society (Joint British Societies [JBS]), their conclusions being supported by the British Diabetic Association. 3 These were particularly helpful, as they incorporated the principles of evidence-based guideline development 4 and emphasized the need to integrate approaches to reduce total CHD risk, an approach that was in line with concurrent developments in Europe and America. In addition, these widely accepted guidelines simpli¢ed the provision of relevant interpretative comment for laboratory investigations contributing to the assessment of CHD risk, such as blood lipids.
Maintaining relevant clinical guidelines is a dynamic process, since the evidence on which they are based is changing continually. It is seven years since the ¢rst JBS recommendations were published and several important studies have added to knowledge in this ¢eld during this period. The advent of updated guidelines is therefore very much to be welcomed. 5
Previous guidelines
The ¢rst JBS guidelines (JBS1) acknowledged that it was necessary to establish priorities in CHD prevention in clinical practice. 3 These were as follows:
(1) Patients with established CHD or other major atherosclerotic disease (secondary prevention);
(2) Individuals without existing CHD but who were at high risk of developing the disease (primary prevention). These were subjects who smoked, had hypertension, dyslipidaemia, diabetes mellitus, a family history of premature CHD or a combination of risk factors.
A staged approach to the management of high-risk individuals in the second category was proposed to ensure that resources for identi¢cation, investigation and management were used appropriately. As a minimum, those with a 10-year risk of developing CHD of 30% or greater were targeted for the most active management, but it was recommended that this should be progressively reduced to patients with a 10-year absolute risk of 15% or greater, as resources allowed. In relation to individual risk factors, the following were recommended as targets:
Bloodpressure o140 mmHg systolic and o80 mmHg diastolic;
Total cholesterol o5.0 mmol/L or LDL cholesterol o3.0 mmol/L; Diabetes mellitus should be optimally controlled and blood pressure (BP) targets should be lower than in the non-diabetic population (130 mmHg systolic and 80 mmHg diastolic).
Two approaches were suggested for calculating CHD risk, a computer program or risk prediction charts, both based on epidemiological data from Framingham. 6 The categorical variables sex, smoking status and whether the patient was diabetic were required, together with data for age, systolic BP and total and HDL cholesterol concentration. Both the computer program and prediction charts were available widely, the latter being included within the British National Formulary.
Evidence base for new guidelines
There has been progress in three main areas:
(1) Re¢ning the basis of risk calculation;
(2) Changing the emphasis of CHD prevention guidelines to include other cardiovascular disease;
(3) Applying the results of research studies, particularly those reporting patient outcomes, to treatment targets.
Risk calculation
Risk calculation has some inherent shortcomings, particularly as the Framingham population is American and predominantly white. Assessments of risk may not therefore be transferable with appropriate accu-racy to other populations with greater ethnic diversity. More speci¢cally, the Framingham risk equation was based on a population that included only 337 diabetic patients and diabetes was treated as a categorical variable (present or absent), rather than including an estimate of severity. 6 The UK Prospective Diabetes Study (UKPDS) included a cohort of 5102 patients followed for over 10 years and data from this have been used to explore the issue of risk prediction in patients with type 2 diabetes. 7 This demonstrates that inclusion of haemoglobin A 1c (HbA 1c ) improves the accuracy of the model and that the risk is higher than predicted using Framingham data, raising the question as to whether risk should be calculated at all in diabetic patients, rather than which prediction model to use. The American Diabetic Association concluded that the risk in diabetic patients is comparable to that in subjects with existing CHD and therefore approaches to the prevention of further cardiovascular episodes should be similar in both the groups. 8 The appropriate lipid variables for determining cardiovascular risk have been debated for some time. The evidence base for the bene¢ts of LDL cholesterol reduction is very clear and all major national and international guidelines have emphasized the importance of this as the primary target for treatment. However, LDL cholesterol measurements during treatment appear to be a relatively poor predictor of outcome, particularly where pre-treatment LDL cholesterol is not particularly elevated. 9 This may be explained on the basis of the variability of LDL composition and the increasing signi¢cance of other atherogenic lipoprotein species at low LDL cholesterol levels, particularly in the presence of hypertriglyceridaemia and in patients with diabetes mellitus. 10 There is some evidence for other lipid variables to be used for risk prediction in treated patients, including apolipoprotein B 11,12 and non-HDL cholesterol. 13 Patients with elevated triglyceride and low HDLcholesterol concentrations bene¢ted most from treatment with gem¢brozil in the Helsinki Heart Study 14 and evidence for bene¢t of increasing HDL cholesterol was shown in Veterans A¡airs High-Density Lipoprotein Intervention Trial (VA-HIT) study. 15
Cardiovascular disease
The ¢rst joint guidelines focused on CHD prevention within the context of this being one aspect of CVD. This was a re£ection of a prioritization approach but it is clear that bene¢ts of prevention also apply to thrombo-embolic stroke and peripheral vascular disease. 16, 17 It is therefore logical to consider vascular disease as a spectrum with common risk factors, with the potential to bene¢t from lifestyle management and appropriate pharmacological interventions. A 10-year CVD risk of 20% is approximately equivalent to a CHD risk of 15% over the same period
Research studies
Several important clinical trials with cardiovascular event endpoints have been published in recent years, adding to earlier landmark studies. 18--22 Positive randomized controlled trials have been reported in the last ¢ve years for simvastatin, 17,23 atorvastatin, 24--28 £uvastatin 29, 30 and pravastatin, 31, 32 adding to the already extensive evidence base for 3-hydroxy-3-methyl glutaryl coenzyme A (HMG CoA) reductase inhibitors. These trials extend the evidence of treatment bene¢t to a number of additional clinical circumstances, most notably to patients with total serum cholesterol concentrations o5.0 mmol/L and LDL cholesterol levels o3.0 mmol/L. 16 In addition, previous subgroup analysis suggesting reduced incidence of CVD in type 2 diabetes has been con¢rmed in a primary prevention study in this group of patients. 25 In general, the reduced incidence of CVD with antihypertensive drugs relates to the degree of reduction in BP rather than to speci¢c e¡ects of the various drug classes. 33--35 Most clinical trials have used combinations of drugs to achieve targets for BP reduction while the majority of patients treated in the UK receive a single antihypertensive agent. 36 While many impressive clinical trials have suggested extended indications for drugs, what of lifestyle changes? The risk of CVD falls rapidly with smoking cessation, coronary mortality being halved in patients who quit following a myocardial infarction. 37 Reducing saturated fat intake together with ensuring regular oily ¢sh intake lowers the incidence of CVD, 38, 39 while a diet rich in fruit and vegetables, with reduced saturated fat and salt content, reduces BP. 40 However, not all proposed dietary interventions have proved bene¢cial since antioxidant vitamin supplements do not reduce cardiovascular risk. 17,41 Aerobic exercise included in cardiac rehabilitation programmes improves life expectancy. 42 
New guidelines
There are several key features of the new guidelines.
(1) Prevention strategies should focus on CVD, not CHD; (2) Strategies should focus on high-risk groups, with equal priority being given to all those with established CVD or diabetes mellitus; (3) Subjects without CVD but with a risk factor pro¢le resulting in an absolute risk of developing CVD X20% over 10 years should be included in these strategies;
(4) CVD prevention should also be applied to subjects with particularly unfavourable single-risk factors, including: (a) familial dyslipidaemias, such as familial hypercholesterolaemia; (b) Hypercholesterolaemia when the total cholesterol: HDL cholesterol ratio is X7.0; (c) Hypertension when the BPX160 mmHg systolic or X100 mmHg diastolic; (d) Lesser degrees of hypertension when there is end-organ damage; (5) The optimal target for total cholesterol is o4.0 mmol/L and for LDL cholesterol o2.0 mmol/L, or a reduction of 25% in total cholesterol and a 30% reduction in LDL cholesterol, whichever achieves lower absolute level; (6) The optimal BP target is o140 mmHg systolic and o85 mmHg diastolic pressure with lower targets in subjects with CVD, diabetes or chronic renal failure (if these conditions are present, treatment should aim to achieve o130 mmHg systolic and o80 mmHg diastolic pressures).
Impact on clinical care
While guidelines that would lead to a reduced incidence of CVD must be welcome, they will have signi-¢cant impact on clinical care. Firstly, implementation of the guidelines will lead to the 'medicalization' of large numbers of people, many of whom appear healthy. Some of these people will su¡er adverse events because of this, ranging from psychological e¡ects to the side-e¡ects of drugs. Second, there will be a huge impact on the NHS. There are around 170,000 new cases of CHD per annum, while the numbers eligible for primary prevention depend on the threshold adopted in cost-e¡ectiveness analysis. The identi¢cation of highrisk individuals would mainly take place in primary care settings. In addition to the impact on general practitioners and nurses, the requirements for dietetic and smoking cessation services would increase and many more subjects would receive drug treatment.
Using current approaches to cost-e¡ectiveness for introducing pharmacological treatment, 3.09 million people in England and Wales have an annual CVD risk level of 2% and meet the lipid criteria of the guidelines. Prescribing costs for statins for these numbers would be »889 million with additional associated costs of »720 million. 43 In addition to statins, the prescription of antiplatelet and antihypertensive therapy would increase. While not all eligible people would receive drugs, either because of choice, lack of ascertainment or response to lifestyle changes, the short-term economic impact of the guidelines is great. In the longer term, there would be bene¢ts from a reduced incidence of CVD.
Not all subjects will respond to ¢rst-line treatment and therefore referrals to specialized lipid and BP clinics will increase.
Impact on laboratory practice
The major impact on laboratory practice will be in relation to tests undertaken to identify high-risk individuals and for treatment monitoring. For lipids, initial assessment can be satisfactorily based on total cholesterol and HDL cholesterol using non-fasting blood. If the initial assessment indicates high risk, then a fasting lipoprotein pro¢le (total and HDL cholesterol, triglycerides and calculated LDL cholesterol) should be undertaken. Treatment decisions will not usually be taken on the basis of one result, unless this is very abnormal, and repeat analysis will be undertaken before most treatment decisions are taken, to allow for biological variation and lifestyle changes. Some additional tests will be required to investigate the possibility of secondary hyperlipidaemia, including assessments of thyroid, liver and renal function, and glycaemic status.
Conclusions
The publication of revised, evidence-based guidelines for the prevention of CVD is welcome. However, the economic impact of their implementation will be considerable, at a time of great other ¢nancial pressures in the National Health Service. It is di⁄cult to see how existing resources available to health-care commissioners can cope with these pressures without material commitment at the highest level.
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